Asp-B25

Drug Profile

Asp-B25

Latest Information Update: 26 Feb 2001

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Nonindustrial source
  • Class Amino acids; Antihyperglycaemics; Insulins
  • Mechanism of Action Phosphokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 26 Feb 2001 No-Development-Reported for Diabetes mellitus in USA (SC)
  • 12 Dec 1997 Preclinical development for Diabetes mellitus in USA (SC)
  • 12 Dec 1997 A study has been added to the Diabetes mellitus pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top